Automation and robotics: The next industrial revolution

Usage reaching a tipping point

clock • 4 min read

Sophia Li, portfolio manager at First State Stewart Asia, on the three driving forces behind the growth in robotics in Japan.

The slow pace of change in Japan and the meagre improvements made so far have been a difficult pill to swallow for Abenomics supporters. On top of the lack of reform, there is the ageing population, a deflationary environment and negative interest rates to contend with. Unfortunately, it is far too easy to get stuck on the top-down negativities when investing in Japan and lose sight of the real investment opportunities on the ground. Tapping into the Internet of Things We have been mindful of this and, while we share the market's concerns at the macro level, we believe that ther...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

While thematic funds offer diversification and a specialist knowledge base, investors must also consider the sensitivity to real bond yields inherent in these funds.

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
Deal volumes fell last year as rising interest rates brought the end of cheap money

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Ali H. Munawar, CEO of Pledge Therapeutics

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot